While diabetes gets a lot of attention, people with Type 1 Diabetes (T1D) are frequently overlooked when drug companies develop new medications. "People with T1D and chronic kidney disease, or CKD, ...
Tolvaptan efficacy was assessed among younger adults 18-35 years with autosomal dominant polycystic kidney disease (ADPKD), who are at high risk for progression.